Skip to main content

Advertisement

SpringerLink
Log in

Effect of thyroid hormone status on complete blood cell count-derived inflammatory biomarkers in patients with moderate-to-severe Graves’ ophthalmopathy

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the systemic inflammation in moderate-to-severe Graves’ ophthalmopathy patients with abnormal thyroid function by using complete blood cell count-derived inflammatory biomarkers and compare to moderate-to-severe GO patients with regulated thyroid function and healthy controls. The second aim is to evaluate the relationship of complete blood cell count-derived inflammatory biomarkers with clinical findings in moderate-to-severe GO.

Methods

In this retrospective study, 90 GO patients with abnormal thyroid function composed Group 1, 58 patients who had normal thyroid function for at least 3 months composed Group 2, and 50 healthy individuals composed Group 3. Demographic data, neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), mean platelet volume (MPV), and systemic immune-inflammatory index (SII) were evaluated.

Results

There was no statistically significant difference between groups in terms of age, sex, and smoking habits (p > 0.05). There was a statistically significant difference in NLR (p = 0.011), MLR (p = 0.013), MPV (p < 0.001), and SII (p < 0.001) values among 3 groups. For NLR, MLR, and SII the highest values were detected in Group 1. MPV levels were higher in Group 3 than Groups 1 and 2 (p < 0.001). None of the hematological parameters were found to be a risk factor for any clinical severity findings of GO.

Conclusion

The higher levels of NLR, MLR, and SII levels may show systemic inflammation in GO patients with abnormal thyroid function, and this may have an impact on the clinical course of ophthalmopathy. These findings may suggest that cautious control of thyroid hormone levels is important in the management of GO.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stan MN, Durski JM, Brito JP, Bhagra S, Thapa P, Bahn RS (2013) Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves’ ophthalmopathy and optimal timing for thyroid hormone assessment. Thyroid 23:620–625

    Article  CAS  PubMed  Google Scholar 

  2. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, Van der Gaag R (1990) Effect of abnormal thyroid function on the severity of Graves’ ophthalmopathy. Arch Intern Med 150:1098–1101

    Article  CAS  PubMed  Google Scholar 

  3. Hao X, Li D, Wu D, Zhang N (2017) The relationship between Hematological Indices and Autoimmune Rheumatic Diseases (ARDs), a meta-analysis. Sci Rep 7:10833

    Article  PubMed  PubMed Central  Google Scholar 

  4. Qin B, Ma N, Tang Q, Wei T, Yang M, Fu H et al (2016) Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were useful markers in assessment of inflammatory response and disease activity in SLE patients. Mod Rheumatol 26:372–376

    Article  PubMed  Google Scholar 

  5. Yavuz S, Ece A (2014) Mean platelet volume as an indicator of disease activity in juvenile SLE. Clin Rheumatol 33:637–641

    Article  PubMed  Google Scholar 

  6. Kisacik B, Tufan A, Kalyoncu U, Karadag O, Akdogan A, Ozturk MA et al (2008) Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine 75:291–294

    Article  PubMed  Google Scholar 

  7. Tanacan E, Dincer D, Erdogan FG, Gurler A (2021) A cutoff value for the systemic immune-inflammation Index in determining activity of Behçet disease. Clin Exp Dermatol 46:286–291

    Article  CAS  PubMed  Google Scholar 

  8. Prummel MF, Bakker A, Wiersinga WM et al (2003) Multicenter study on the characteristics and treatment strategies of patients with Graves’ orbitopathy: the first European Group on Graves’ Orbitopathy experience. Eur J Endocrinol 148:491–495

    Article  CAS  PubMed  Google Scholar 

  9. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L (1997) Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 47:9–14

    Article  CAS  PubMed  Google Scholar 

  10. Bartalena L, Kahaly GJ, Baldeschi L, Dayan MC, Eckstein A, Marcocci C et al (2021) The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol 185:G43–G67

    Article  CAS  PubMed  Google Scholar 

  11. Aranow H, Day RM (1965) Management of thyrotoxicosis in patients with ophthalmopathy: antithyroid regimen determined primarily by ocular manifestations. J Clin Endocrinol Metab 25:1–10

    Article  PubMed  Google Scholar 

  12. Solem JH, Segaard E, Ytteborg J (1979) The course of endocrine ophthalmopathy during antithyroid therapy in a prospective study. Acta Med Scand 205:111–114

    Article  CAS  PubMed  Google Scholar 

  13. Klecha AJ, Barreiro Arcos ML, Frick L, Genaro AM, Cremaschi G (2008) Immune-endocrine interactions in autoimmune thyroid diseases. NeuroImmunoModulation 15:68–75

    Article  CAS  PubMed  Google Scholar 

  14. Bartalena L, Tanda ML (2022) Current concepts regarding Graves’ orbitopathy. J Intern Med 292:692–716

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Rydzewska M, Jaromin M, Pasierowska IE, Stozek K, Bossowski A (2018) Role of the T and B lymphocytes in pathogenesis of autoimmune thyroid diseases. Thyroid Res 11:2

    Article  PubMed  PubMed Central  Google Scholar 

  16. Kaplan MJ (2013) Role of neutrophils in systemic autoimmune diseases. Arthritis Res Ther 15:219

    Article  PubMed  PubMed Central  Google Scholar 

  17. Zhu L, Huang Z, Stålesen R, Hansson GK, Li N (2014) Platelets provoke distinct dynamics of immune responses by differentially regulating CD4+ T-cell proliferation. J Thromb Haemost 12:1156–1165

    Article  CAS  PubMed  Google Scholar 

  18. Habets KL, Huizinga TW, Toes RE (2013) Platelets and autoimmunity. Eur J Clin Invest 43:746–757

    Article  CAS  PubMed  Google Scholar 

  19. Szczepanek-Parulska E, Adamska M, Korda O, Kosicka W, Skowronska D, Swiejkowska A et al (2021) Changes in complete blood count parameters influenced by endocrine disorders. Endokrynol Pol 72:261–270

    Article  CAS  PubMed  Google Scholar 

  20. Taskaldiran I, Omma T, Onder CE, Firat SN, Koc G, Kilic MK et al (2019) Neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and platelet-tolymphocyte ratio in different etiological causes of thyrotoxicosis. Turk J Med Sci 49:1687–1692

    PubMed  PubMed Central  Google Scholar 

  21. Margraf A, Perretti M (2022) Immune cell plasticity in ınflammation: ınsights into description and regulation of ımmune cell phenotypes. Cells 11:1824

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Naji P, Kumar G, Dewani S, Diedrich WA, Gupta A (2013) Graves’ disease causing pancytopenia and autoimmune hemolytic anemia at different time intervals: a case report and a review of the literature. Case Rep Med 2013:194542

    Article  PubMed  PubMed Central  Google Scholar 

  23. Szczepanek-Parulska E, Hernik A, Ruchała M (2017) Anemia in thyroid diseases. Pol Arch Intern Med 127:352–360

    PubMed  Google Scholar 

  24. Turan E (2019) Evaluation of neutrophil-to-lymphocyte ratio and hematologic parameters in patients with Graves’ disease. Bratisl Lek Listy 120:476–480

    CAS  PubMed  Google Scholar 

  25. Kim M, Kim BH, Jang MH, Kim MJ, Kim EH, Jeon YK et al (2020) High neutrophil-to-lymphocyte ratio is associated with relapse in Graves’ disease after antithyroid drug therapy. Endocrine 67:406–411

    Article  CAS  PubMed  Google Scholar 

  26. Celik T (2017) Neutrophil-to-lymphocyte ratio in thyroid ophthalmopathy. Bratisl Lek Listy 118:495–498

    CAS  PubMed  Google Scholar 

  27. Yeter V, Kocak N, Arslan MT, Kan EK (2021) Blood count-derived Immunoinflammatory markers in thyroidassociated ophthalmopathy. Korean J Ophthalmol 35:198–206

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Xu Y, He H, Zang Y, Yu Z, Hu H, Cui J et al (2022) Systemic inflammation response index (SIRI) as a novel biomarker in patients with rheumatoid arthritis: a multi-center retrospective study. Clin Rheumatol 41:1989–2000

    Article  PubMed  Google Scholar 

  29. Szydełko J, Litwińczuk M, Szydełko M, Matyjaszek-Matuszek B (2020) Neutrophil-to-lymphocyte, monocyte-to-lymphocyte and platelet-to-lymphocyte ratios in relation to clinical parameters and smoking status in patients with graves’ orbitopathy-novel ınsight into old tests. J Clin Med 9:3111

    Article  PubMed  PubMed Central  Google Scholar 

  30. Korniluk A, Koper-Lenkiewicz OM, Kamińska J, Kemona H, Dymicka-Piekarska V (2019) Mean platelet volume (MPV): new perspectives for an old marker in the course and prognosis of ınflammatory conditions. Mediators Inflamm 2019:9213074

    Article  PubMed  PubMed Central  Google Scholar 

  31. Sahin A, Yetisgin A, Sahin M, Durmaz Y, Cengiz AK (2015) can mean platelet volume be a surrogate marker of ınflammation in rheumatic diseases? West Indian Med J 65:165–169

    CAS  PubMed  Google Scholar 

  32. Jenne CN, Kubes P (2015) Platelets in inflammation and infection. Platelets 26:286–292

    Article  CAS  PubMed  Google Scholar 

  33. Lippi G, Franchini M (2015) Platelets and immunity: the interplay of mean platelet volume in health and disease. Expert Rev Hematol 8:555–557

    Article  CAS  PubMed  Google Scholar 

  34. Kim JM, LaBree L, Levin L, Feldon SE (2004) The relation of Graves’ ophthalmopathy to circulating thyroid hormone status. Br J Ophthalmol 88:72–74

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Totterman TH, Karlsson FA, Bengtsson M, Mendel-Hartvig I (1987) Induction of circulating activated suppressor-like T cells by methimazole therapy for Graves’ disease. N Engl J Med 316:15–22

    Article  CAS  PubMed  Google Scholar 

  36. Kuroki T, Ruf J, Whelan L, Miller A, Wall JR (1985) Antithyroglobulin monoclonal and autoantibodies cross-react with an orbital connective tissue membrane antigen: a possible mechanism for the association of ophthalmopathy with autoimmune thyroid disorders. Clin Exp Immunol 62:361–370

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Kamminga N, Jansonius NM, Pott JWR, Links TP (2003) Unilateral proptosis: the role of medical history. Br J Ophthalmol 87:370–371

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Perros P, Crombie AL, Matthews JN, Kendall-Taylor P (1993) Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clin Endocrinol (Oxf) 38:367–372

    Article  CAS  PubMed  Google Scholar 

  39. Silva JE, Bianco SDC (2008) Thyroid-adrenergic interactions: physiological and clinical implications. Thyroid 18:157–165

    Article  CAS  PubMed  Google Scholar 

  40. Cant JS, Lewis DR, Harrison MT (1969) Treatment of dysthyroid ophthalmopathy with local guanethidine. Br J Ophthalmol 53:233–238

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Prummel MF, Wiersinga WM (1993) Smoking and risk of Graves’ disease. JAMA 269:479–482

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Ophthalmic Plastic Surgery Service, Ankara Bilkent City Hospital, Universiteler Mah 1604. Cadde No:9 Bilkent, Çankaya, 06800, Ankara, Turkey

    Nilay Yuksel

  2. Department of Ophthalmology, Ankara Bilkent City Hospital, Ankara, Turkey

    Ozge Saritas

  3. Department of Ophthalmology, Medical Faculty, Kastamonu University, Kastamonu, Turkey

    Erdem Yuksel

Authors
  1. Nilay Yuksel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ozge Saritas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Erdem Yuksel
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

NY wrote the main manuscript text. OS collected the data. EY did the statistical analysis. All authors reviewed the manuscript.

Corresponding author

Correspondence to Nilay Yuksel.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest and financial interest in any part of this study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yuksel, N., Saritas, O. & Yuksel, E. Effect of thyroid hormone status on complete blood cell count-derived inflammatory biomarkers in patients with moderate-to-severe Graves’ ophthalmopathy. Int Ophthalmol 43, 3355–3362 (2023). https://doi.org/10.1007/s10792-023-02742-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-023-02742-x

Keywords

Search

Navigation